Sponsored by
This is a new way of delivery radiation to the tumor using nanoliposomes and Rhenium-186. Visit their website https://www.plustherapeutics.com/ to see how it works. This phase 1 trial had impressive results: It was a dose finding trial. Those at the highest dose did not have any dose limiting toxcicities and 7 of 13 recurrent glioblastoma patients are still alive at an average of 453 days. This compares very favorably to history which tells us these patients live about 6 months (183 days). The trial for recurrent glioblastoma is still open, and they will soon start trials for pediatric brain tumors and leptomeningeal metastases.